Daewoong Pharmaceutical announced on the 12th that its wearable electrocardiogram (ECG) testing solution “mobiCARE” has successfully achieved early detection of arrhythmia at the health checkup stage, identifying cases that had been missed by conventional examinations.

According to Daewoong Pharmaceutical, during a health checkup at the Gyeongnam branch of the Korea Association of Health Promotion, “atrial tachycardia” was detected early in a female examinee in her late 60s through a one-day arrhythmia screening test using mobiCARE.

The examinee, who had been experiencing chest pain when walking uphill, underwent an additional mobiCARE test alongside a conventional 12-lead ECG. However, it was reported that the short-duration 12-lead ECG, which is completed in a brief time, did not show any abnormal findings. In contrast, the one-day mobiCARE screening identified signs of atrial tachycardia, and based on this result, she was immediately referred for consultation in the cardiology department.

Subsequently, coronary angiography was performed at a general hospital, revealing mild stenosis, and she is currently receiving concurrent drug treatment.

The 12-lead ECG commonly conducted in routine health checkups verifies cardiac status over approximately 10 seconds, making it difficult to detect intermittent arrhythmias that do not occur at the exact time of the examination. mobiCARE involves attaching an ultra-lightweight device weighing about 19 grams and continuously measuring ECG over one to nine days. It provides AI-based analysis and interpretation reports by arrhythmia specialists, enabling its use even at screening centers where cardiology specialists are not on site.

Park Cheol, Head of Medical Services at the Gyeongnam branch of the Korea Association of Health Promotion (thoracic surgery specialist), said, “Arrhythmias are often difficult to detect with short ECG tests alone, so long-term monitoring-based examinations like mobiCARE can be of great help.”

Cho Byoung-ha, Head of the Digital Healthcare Division at Daewoong Pharmaceutical, said, “Daewoong will continue to support active use of the latest digital healthcare solutions in clinical settings and screening institutions, thereby contributing to the spread of an early detection and prevention-centered health management system.”

Popular News